Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... Md. (PRWEB) , ... June ... ... leading provider of gene-to-protein and monoclonal antibody development services, today announced that ... protein-based products and services to the pharmaceutical, diagnostics, and research industries. The ...
(Date:6/23/2020)... ... June 23, 2020 , ... In its June 22 online post, business ... James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company ... June 16 that starting July 5 it would begin offering free tissue ...
(Date:6/13/2020)... ... 2020 , ... Bode Technology (Bode), a leading ... team. Bode’s Forensic Genealogy Service (FGS) continues to deliver investigative leads ... The team has added experienced genealogists, each having over a decade of field ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 23, 2020 , ... ... therapies, today announced that it has filed an Investigational New Drug application (IND) ... clinical trial of its lead drug candidate NBTX-001 in patients with panic disorder ...
(Date:6/11/2020)... (PRWEB) , ... June 09, 2020 , ... Reducing carbon ... the world. From the Paris Agreement to stock market dips, ways to reduce CO2 ... adding biofuels to their portfolio. Most of the biofuels being produced today are created ...
(Date:5/28/2020)... ... May 28, 2020 , ... Genedata, the leading provider ... Genedata Screener ® 17.0, the latest version of its enterprise software for the ... technologies. Genedata will host a webinar on June 10, 2020, detailing and demonstrating ...
(Date:5/21/2020)... ... , ... Eaton Square is pleased to announce its growth on the East ... medical technology-focused strategy and M&A advisory firm. , This is an important step for ... Asia Pacific healthcare innovators with capital and investors. , Popper and Company, founded in ...
Breaking Biology Technology: